Regulation of Colonic Mucosal MicroRNA Expression Via Multiple Targets in Visceral Hypersensitivity Rats by Tongxieyaofang

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2018 Sep 7

PMID 30187701

Citations 3

Authors

Guanqun Chao

Yingying Wang

Fangxu Ye

Shuo Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to screen for differentially expressed microRNAs (miRNAs) in the colons of rats with visceral hypersensitivity to build the expression profiles of miRNAs therein and to determine the mechanism of Tongxieyaofang use in the treatment of irritable bowel syndrome (IBS).

Materials And Methods: Forty Sprague-Dawley rats were divided randomly into four groups: control group, model control group (induced by rectum stimulus and evaluated by abdominal withdraw reaction), treatment control group (normal saline), and Tongxieyaofang group (treated with Tongxieyaofang). We screened for differential expression of colonic mucosal miRNAs using liquid chip technology and verified the expression thereof using reverse transcription-PCR.

Results: The visceral hypersensitivity rat model was successfully established. We found the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 to be up-regulated (<0.05), while the expression of miR-24, miR-31a, miR-192, miR-221, and miR-223 was down-regulated (<0.05) in the visceral hypersensitivity rats. After treatment with Tongxieyaofang, the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 was reduced (<0.05), whereas the expression of miR-24, miR-31a, miR-192, miR-221, miR-223 was increased, compared to the treatment control group (<0.05).

Conclusion: MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang.

Citing Articles

Efficacy of Tong-Xie-Yao-Fang granule and its impact on whole transcriptome profiling in diarrhea-predominant irritable bowel syndrome patients: study protocol for a randomized controlled trial.

Wang Y, Huang Y, Zhu S, Zhang C, Chen X, Hou Q Trials. 2020; 21(1):908.

PMID: 33143731 PMC: 7607547. DOI: 10.1186/s13063-020-04833-x.

Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1.

Zhu H, Xiao X, Shi Y, Wu Y, Huang Y, Li D Exp Ther Med. 2020; 20(6):155.

PMID: 33093893 PMC: 7571313. DOI: 10.3892/etm.2020.9284.

Clinical Effects and Safety of Tongxieyaofang on Diarrhea Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized Trails.

Zhou Y, Han S, He Y Evid Based Complement Alternat Med. 2019; 2019:4893876.

PMID: 30723513 PMC: 6339716. DOI: 10.1155/2019/4893876.

References

Liao X, Mao W, Wang Q, Yang G, Wu W, Shao S . MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun. 2015; 469(2):288-93. DOI: 10.1016/j.bbrc.2015.11.102. View

Rieger J, Reutter S, Hofmann U, Schwab M, Zanger U . Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos. 2015; 43(6):884-8. DOI: 10.1124/dmd.114.062844. View

Lin X, Zheng X, Fan D, Yao Q, Hu J, Lian L . MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease. Inflamm Bowel Dis. 2018; 24(4):781-791. DOI: 10.1093/ibd/izx075. View

Szucs D, Beres N, Rokonay R, Boros K, Borka K, Kiss Z . Increased duodenal expression of miR-146a and -155 in pediatric Crohn's disease. World J Gastroenterol. 2016; 22(26):6027-35. PMC: 4948267. DOI: 10.3748/wjg.v22.i26.6027. View

Zhou Q, Zhang B, Verne G . Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009; 146(1-2):41-6. PMC: 2763174. DOI: 10.1016/j.pain.2009.06.017. View

Zhou Q, Yang L, Larson S, Basra S, Merwat S, Tan A . Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut. 2015; 65(5):797-805. PMC: 4853572. DOI: 10.1136/gutjnl-2013-306464. View

Corsetti M, Van Oudenhove L, Tack J . The quest for biomarkers in IBS-where should it lead us?. Neurogastroenterol Motil. 2014; 26(12):1669-76. DOI: 10.1111/nmo.12475. View

Hu X, Xu D, Zhao Y, Yang X, Meng J, Shen H . The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism. Biol Pharm Bull. 2009; 32(6):1075-9. DOI: 10.1248/bpb.32.1075. View

Zhou Q, Verne G . New insights into visceral hypersensitivity--clinical implications in IBS. Nat Rev Gastroenterol Hepatol. 2011; 8(6):349-55. PMC: 3437337. DOI: 10.1038/nrgastro.2011.83. View

10.

Farh K, Grimson A, Jan C, Lewis B, Johnston W, Lim L . The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005; 310(5755):1817-21. DOI: 10.1126/science.1121158. View

11.

Olaru A, Selaru F, Mori Y, Vazquez C, David S, Paun B . Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis. 2010; 17(1):221-31. PMC: 3006011. DOI: 10.1002/ibd.21359. View

12.

Xu X, Gao F, Wang J, Tao L, Ye J, Ding L . MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther. 2018; 19(5):427-435. PMC: 5915035. DOI: 10.1080/15384047.2018.1423925. View

13.

Verne N, Robinson M, Price D . Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain. 2001; 93(1):7-14. DOI: 10.1016/S0304-3959(01)00285-8. View

14.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

15.

Yang Q, Xu X, Zhao H, Cai Y, Pan Y, Xu J . Differential expression of microRNA related to irritable bowel syndrome in a rabbit model. J Dig Dis. 2017; 18(6):330-342. DOI: 10.1111/1751-2980.12485. View

16.

Kim H, Banerjee N, Sirven M, Minamoto Y, Markel M, Suchodolski J . Pomegranate polyphenolics reduce inflammation and ulceration in intestinal colitis-involvement of the miR-145/p70S6K1/HIF1α axis in vivo and in vitro. J Nutr Biochem. 2017; 43:107-115. DOI: 10.1016/j.jnutbio.2017.02.005. View

17.

Sima X, Sun H, Zhou P, You C . A Potential Polymorphism in the Promoter of Let-7 is Associated With an Increased Risk of Intracranial Aneurysm: A Case-Control Study. Medicine (Baltimore). 2015; 94(51):e2267. PMC: 4697975. DOI: 10.1097/MD.0000000000002267. View

18.

Liao H, Banbury L, Leach D . Elucidation of danzhixiaoyao wan and its constituent herbs on antioxidant activity and inhibition of nitric oxide production. Evid Based Complement Alternat Med. 2008; 4(4):425-30. PMC: 2176144. DOI: 10.1093/ecam/nel091. View

19.

Johnston D, Williams M, Thaiss C, Cabrera-Rubio R, Raverdeau M, McEntee C . Loss of MicroRNA-21 Influences the Gut Microbiota, Causing Reduced Susceptibility in a Murine Model of Colitis. J Crohns Colitis. 2018; 12(7):835-848. DOI: 10.1093/ecco-jcc/jjy038. View

20.

Sun Y, Jin X, Liu X, Zhang M, Liu W, Li Z . MicroRNA let-7i regulates dendritic cells maturation targeting interleukin-10 via the Janus kinase 1-signal transducer and activator of transcription 3 signal pathway subsequently induces prolonged cardiac allograft survival in rats. J Heart Lung Transplant. 2016; 35(3):378-388. DOI: 10.1016/j.healun.2015.10.041. View